GoodRx reports Q2 EPS 4c, consensus 10c

Reports Q2 revenue $203.1M, consensus $205.71M. “I’m excited about the meaningful progress we made during the second quarter delivering against our key initiatives that are designed to better position the Company for sustainable long-term growth,” said Wendy Barnes, Chief Executive Officer and President of GoodRx (GDRX). “We are effectively creating value for core stakeholders-we expanded our integrated access and affordability solutions with pharma, finalized several new deals for pharmacy counter and e-commerce solutions, and announced the launch of our new condition subscription product for erectile dysfunction. I am confident in our positive momentum and believe GoodRx is in a strong position to reduce friction in the system and serve as the complement to insurance that helps consumers access and afford the medications they need.”